What's Happening?
Profound Therapeutics, led by CEO John Lepore, is utilizing a novel approach combining ribosome-level profiling and artificial intelligence to map thousands of previously uncatalogued proteins across over 500 human cell types and tissues. This method
challenges the traditional understanding of the human proteome, which has largely been limited to approximately 20,000 proteins identified by the Human Genome Project. Lepore argues that the previous limitations were due to restrictive annotation rules, such as minimum amino acid length and canonical start/stop codons. Profound's platform loosens these rules, examining translation events at the ribosome level and confirming proteins via mass spectrometry. This industrial-scale effort aims to identify a vast, genetically validated pool of first-in-class drug targets for various diseases, including oncology, preeclampsia, and neuroscience. The company has already secured collaborations with major pharmaceutical firms like GSK, Pfizer, and Novartis, focusing on genetics-led target discovery in areas such as COPD, IPF, obesity, and cardiovascular disease.
Why It's Important?
This advancement holds significant implications for drug discovery and development. By uncovering a previously hidden proteome, Profound Therapeutics is expanding the potential landscape for therapeutic interventions. The identification of novel, genetically validated protein targets could lead to the development of entirely new classes of medicines, addressing unmet medical needs in various disease areas. For instance, in oncology, the discovery of novel tumor antigens that are highly enriched in cancer cells and minimally expressed in healthy tissue could enable the creation of more precise and effective antibody-drug conjugates (ADCs) and T-cell engagers with reduced side effects. Furthermore, the genetics-led prioritization of targets for cardiovascular, metabolic, immune, and neuro programs increases the likelihood of successful clinical outcomes, as genetically associated targets have shown a two- to tenfold higher chance of positive results. This approach could revolutionize how drug targets are identified and validated, potentially accelerating the development of breakthrough therapies.
What's Next?
Profound Therapeutics plans to continue expanding its mapping efforts, aiming to characterize proteins across an even broader range of human cell types. The company's oncology programs, which are developing ADCs and T-cell engagers against novel antigens, are expected to progress rapidly, with IND (Investigational New Drug) filings anticipated in the future. Further collaborations with pharmaceutical partners are also expected as the platform continues to yield new, genetically validated targets. The Gates Foundation grant for preeclampsia research will focus on comparing placental tissue from women with and without the condition to identify differentially expressed proteins, including those from the expanded proteome, to find drug targets and biomarkers. This collaboration also aims to develop an AI agent trained on preeclampsia biology. The long-term goal is to translate these newly discovered proteins into effective treatments for a wide array of diseases, moving beyond the current limitations of known protein targets.
Beyond the Headlines
The work by Profound Therapeutics challenges fundamental assumptions about the completeness of our understanding of the human genome and its protein products. The concept of a 'dark proteome' suggests that a significant portion of biological activity has remained unobserved, potentially holding keys to understanding complex diseases and developing novel treatments. This paradigm shift could lead to a re-evaluation of existing biological models and drug discovery strategies. Ethically, the ability to precisely target disease-specific proteins with minimal impact on healthy tissues could lead to therapies with fewer side effects, improving patient quality of life. Legally, the company is building a multi-layered intellectual property defense, including patents on its experimental and computational methods, confidentiality of protein identities, and composition-of-matter patents on molecules or even the new proteins themselves. This comprehensive approach to IP will be crucial in protecting its discoveries and commercializing future drugs. Culturally, this research underscores the ongoing evolution of scientific understanding, demonstrating that even well-established fields like genomics and proteomics still hold vast unexplored territories.













